Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.00, near the low end of its 5-year range (0.00–0.00).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 470 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$194.49M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$193.74M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$203.00M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.71M
Debt to Equity Ratio
0.80
TTM Avg
1.04
3Y Avg
1.07
5Y Avg
0.91
Market Cap
$178.54M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$177.29M
Debt to Equity Ratio
3.81
TTM Avg
0.34
3Y Avg
0.34
5Y Avg
0.27
Market Cap
$173.34M
Debt to Equity Ratio
0.62
TTM Avg
0.42
3Y Avg
0.73
5Y Avg
0.54
Market Cap
$169.95M
Debt to Equity Ratio
0.62
TTM Avg
0.66
3Y Avg
0.66
5Y Avg
2.14
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $194.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $193.74M | 0.01 | 0.01 | 0.02 | 0.01 |
| Electra Therapeutics Inc. (ETRA)vs › | $203.00M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $183.71M | 0.80 | 1.04 | 1.07 | 0.91 |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cue Biopharma, Inc. (CUE)vs › | $177.29M | 3.81 | 0.34 | 0.34 | 0.27 |
| Compugen Ltd. (CGEN)vs › | $218.42M | 0.03 | 0.04 | 0.03 | 0.03 |
| Precision BioSciences, Inc. (DTIL)vs › | $173.34M | 0.62 | 0.42 | 0.73 | 0.54 |
| Coherus Oncology, Inc. (CHRS)vs › | $169.95M | 0.62 | 0.66 | 0.66 | 2.14 |
| Compass Therapeutics, Inc. (CMPX)vs › | $171.61M | 0.06 | 0.05 | 0.03 | 0.07 |
Debt/Equity
0.00
Current Ratio
14.32
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
